carmustine has been researched along with Granulocytic Leukemia, Chronic in 7 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eleven patients with acute myeloblastic leukemia (AML) beyond the first complete remission or chronic myelogenous leukemia (CML) not in first chronic phase received an association of 13." | 1.29 | Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies. ( Bourdin, S; Harousseau, JL; Le Tortorec, S; Mahe, B; Mahe, JM; Mechinaud-Lacroix, F; Milpied, N; Moreau, P; Rapp, MJ; Wu, DP, 1994) |
| "Fifteen patients had chronic myelogenous leukemia in chronic phase or acute leukemia in first remission (standard risk) and twenty-eight patients with more advanced disease (high risk)." | 1.28 | Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. ( Andersson, BS; Brunner, LJ; Huan, SD; LeMaistre, CF; Spencer, V; Spinolo, JA; Spitzer, G; Wallerstein, RO; Woo, SY; Yau, JC, 1992) |
| "Fifteen patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who were ineligible for allogeneic bone marrow transplantation (BMT) or alpha-interferon therapy were included in this study." | 1.28 | Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. ( Deisseroth, AB; Dicke, K; Jagannath, S; Kantarjian, HM; LeMaistre, CF; Spinolo, J; Spitzer, G; Talpaz, M; Yau, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allay, JA | 1 |
| Dumenco, LL | 1 |
| Koc, ON | 1 |
| Liu, L | 1 |
| Gerson, SL | 1 |
| Wu, DP | 1 |
| Milpied, N | 1 |
| Moreau, P | 1 |
| Mechinaud-Lacroix, F | 1 |
| Mahe, B | 1 |
| Le Tortorec, S | 1 |
| Rapp, MJ | 1 |
| Bourdin, S | 1 |
| Mahe, JM | 1 |
| Harousseau, JL | 1 |
| Frischer, H | 1 |
| Kennedy, EJ | 1 |
| Chigurupati, R | 1 |
| Sivarajan, M | 1 |
| Meloni, G | 1 |
| Capria, S | 1 |
| Vignetti, M | 1 |
| Mandelli, F | 1 |
| Modena, V | 1 |
| Yau, JC | 1 |
| LeMaistre, CF | 2 |
| Andersson, BS | 1 |
| Huan, SD | 1 |
| Wallerstein, RO | 1 |
| Woo, SY | 1 |
| Spitzer, G | 2 |
| Spinolo, JA | 1 |
| Spencer, V | 1 |
| Brunner, LJ | 1 |
| Kantarjian, HM | 1 |
| Talpaz, M | 1 |
| Spinolo, J | 1 |
| Yau, J | 1 |
| Dicke, K | 1 |
| Jagannath, S | 1 |
| Deisseroth, AB | 1 |
| Kolb, HJ | 1 |
| Bender-Götze, C | 1 |
| Haas, RJ | 1 |
| Holler, E | 1 |
| Thierfelder, S | 1 |
| Wilmanns, W | 1 |
1 trial available for carmustine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamid | 1989 |
6 other studies available for carmustine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells.
Topics: Animals; Base Sequence; Bone Marrow Cells; Carmustine; Drug Resistance; Genetic Vectors; Hematopoiet | 1995 |
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1994 |
Glutathione, cell proliferation, and 1,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia.
Topics: Buthionine Sulfoximine; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA Repair; DNA, Neoplasm; | 1993 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; | 1997 |
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy | 1992 |
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1991 |